Observed in pilot human work A 2025 IV infusion pilot of BPC-157 in two adults at 10 mg and 20 mg reported no adverse effects on cardiac, hepatic, renal, thyroid, or glucose biomarkers (Lee et al., Alternative Therapies in Health and Medicine, 2025)
A 5 mg BPC-157 vial ($30-50) lasts 10-20 days at 250-500 mcg daily
Peptide Sciences tests this per batch
Conclusion From the compiled animal studies, BPC-157 and TB-500 together represent a dual-modality regenerative systemBPC-157 drives vascular and endothelial normalization, while TB-500 orchestrates cellular movement and matrix formation
Oncogenic Potential (Cancer Risk) Both peptides encourage angiogenesis (blood vessel growth) and cell proliferation
Researchers utilise this compound in laboratory models to investigate cellular energy homeostasis and NAD+ salvage pathways